Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Medtronic
Merck
Johnson and Johnson
Boehringer Ingelheim
Harvard Business School
Express Scripts

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR KEFZOL


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Kefzol

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00550290 ↗ Prophylactic Antibiotics for Prevention of Wound Complications Following Vulvectomy Completed Aultman Health Foundation Phase 4 2007-10-01 This randomized prospective study will specifically investigate the efficacy of a 24 hour post-operative course of broad-spectrum prophylactic antibiotics - namely Cefazolin - in preventing wound infection and wound breakdown following vulvectomy.
NCT01295606 ↗ Cefazolin Pharmacokinetics: Elimination Clearance in Neonates Completed Universitaire Ziekenhuizen Leuven Phase 4 2011-02-01 To document cefazolin disposition (concentration/time profile, protein binding, metabolism, renal elimination characteristics) and its covariates in neonates following intravenous administration of the drug at induction of anesthesia, prior to an invasive procedure To evaluate if optimalisation of cefazolin dose regimen during neonatal life is needed
NCT01991834 ↗ Antibiotic Prophylaxis in Gynecologic Laparoscopy Completed Universidade do Vale do Sapucai N/A 2013-09-01 Laparoscopy is a surgical procedure indicated for most gynecological pathologies and presents numerous advantages over laparotomy, among them lower rates of surgical site infection and less comorbidity feverish. Despite this, the use of antibiotic prophylaxis is widely accepted and performed by most gynecologists. However, there isn't literature evidence to support the routine use of antibiotics in the prophylaxis of wound infection on laparoscopic pelvic surgery .Therefore, this study will evaluate the need for the use of antibiotic prophylaxis in gynecological laparoscopies not including opening hollow viscera.
NCT02078895 ↗ Randomization of Botox for Stent Pain and Irritative Voiding Symptoms Terminated University of California, Irvine Phase 3 2014-02-01 Botulinum toxin type A (Botox A) has shown great success in treating certain urologic conditions. A recent study has documented that Botox injected around the ureteral orifice (or place where the tube that connects the kidney to the bladder enters the bladder), during placement of a ureteral stent (small rubber tube that facilitate drainage of urine from the kidney to the bladder), resulted in a marked decline in the amount of stent pain experienced by patients. This finding was quite remarkable as stents are commonly used in many Urologic conditions, and these stents produce a remarkable degree of patient discomfort. Despite the great improvement in pain reduction, the irritative voiding symptoms [frequent need to void, urgency, burning with urination (dysuria) or nighttime voiding (nocturia)] were not ameliorated by the Botox injections in the ureteral orifice. However, it has already been well documented that in other clinical settings, administrations of Botox into the bladder muscle, has been shown to reduce these irritative symptoms. The objective of the study is to determine if pain and irritative lower urinary tract symptoms related to ureteral stent placement will improve after the injection of Botox around the ureteral orifice and in the bladder itself.
NCT02216227 ↗ Checklist to Prevent MRSA Surgical Site Infections Completed Iowa City Veterans Affairs Medical Center N/A 2014-04-01 The goals of this project are 1) to assess the effectiveness and cost-effectiveness of the checklist to prevent MRSA SSIs among Veterans undergoing TJA or cardiac surgery, and 2) to assess barriers and facilitators to checklist implementation. Hypotheses: 1. The SSI checklist will be effective at reducing MRSA SSIs among total joint arthroplasty and cardiac surgery patients. 2. Implementation of the checklist will be associated with an overall reduction in SSIs caused by all pathogens. 3. The SSI Checklist will be cost-saving since it will prevent many expensive SSIs. 4. Preoperative MRSA testing will be a modifiable barrier to implementing the SSI checklist.
NCT02216227 ↗ Checklist to Prevent MRSA Surgical Site Infections Completed VA Office of Research and Development N/A 2014-04-01 The goals of this project are 1) to assess the effectiveness and cost-effectiveness of the checklist to prevent MRSA SSIs among Veterans undergoing TJA or cardiac surgery, and 2) to assess barriers and facilitators to checklist implementation. Hypotheses: 1. The SSI checklist will be effective at reducing MRSA SSIs among total joint arthroplasty and cardiac surgery patients. 2. Implementation of the checklist will be associated with an overall reduction in SSIs caused by all pathogens. 3. The SSI Checklist will be cost-saving since it will prevent many expensive SSIs. 4. Preoperative MRSA testing will be a modifiable barrier to implementing the SSI checklist.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Kefzol

Condition Name

Condition Name for Kefzol
Intervention Trials
Surgical Site Infection 1
Surgical Wound Infection 1
Wound Infection 1
Breast Neoplasms 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Kefzol
Intervention Trials
Infections 3
Communicable Diseases 2
Wounds and Injuries 2
Wound Infection 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Kefzol

Trials by Country

Trials by Country for Kefzol
Location Trials
United States 13
Brazil 1
China 1
Iran, Islamic Republic of 1
Netherlands 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Kefzol
Location Trials
Wisconsin 1
Utah 1
Texas 1
Oregon 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Kefzol

Clinical Trial Phase

Clinical Trial Phase for Kefzol
Clinical Trial Phase Trials
Phase 4 3
Phase 3 2
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Kefzol
Clinical Trial Phase Trials
Completed 6
Not yet recruiting 1
Terminated 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Kefzol

Sponsor Name

Sponsor Name for Kefzol
Sponsor Trials
National University Hospital, Singapore 1
VA Office of Research and Development 1
Ng Teng Fong General Hospital 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Kefzol
Sponsor Trials
Other 22
U.S. Fed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Express Scripts
Colorcon
Mallinckrodt
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.